{"id":9238,"date":"2025-12-19T23:02:40","date_gmt":"2025-12-19T23:02:40","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/12\/19\/cytokinetics-heart-drug-myqorzo-fda-approval\/"},"modified":"2025-12-19T23:02:40","modified_gmt":"2025-12-19T23:02:40","slug":"cytokinetics-heart-drug-myqorzo-fda-approval","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/12\/19\/cytokinetics-heart-drug-myqorzo-fda-approval\/","title":{"rendered":"STAT+: Cytokinetics heart drug wins FDA approval, the biotech\u2019s first"},"content":{"rendered":"<p>    STAT+: Cytokinetics heart drug wins FDA approval, the biotech\u2019s first<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>It took 27 years, but Cytokinetics secured its first U.S. drug approval.<\/p>\n<p>On Friday, the Food and Drug Administration cleared the new medicine, called Myqorzo, to treat patients with obstructive hypertrophic cardiomyopathy, an inherited heart disorder.\u00a0<\/p>\n<p>Cytokinetics said it will begin selling Myqorzo in late January at a price not yet disclosed. It will compete against a similar drug from Bristol Myers Squibb that was approved in 2022 and is now bringing in more than $1 billion in sales on an annualized basis, and growing.\u00a0<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/12\/19\/cytokinetics-heart-drug-myqorzo-fda-approval\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Adam Feuerstein<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/12\/19\/cytokinetics-heart-drug-myqorzo-fda-approval\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Cytokinetics heart drug wins FDA approval, the biotech\u2019s first It took 27 years, but Cytokinetics secured its first U.S. drug approval. On Friday, the Food and Drug Administration cleared the new medicine, called Myqorzo, to treat patients with obstructive hypertrophic cardiomyopathy, an inherited heart disorder.\u00a0 Cytokinetics said it will begin selling Myqorzo in late [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,2486,2146,2155,2152],"tags":[2150],"class_list":["post-9238","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-cardiovascular-disease","category-fda","category-pharmaceuticals","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/9238"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=9238"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/9238\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=9238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=9238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=9238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}